Description
Light-Based Therapy for Dry AMD
Valeda™ by LumiThera is the first and only FDA-approved Photobiomodulation (PBM) system for the treatment of Dry Age-Related Macular Degeneration (Dry AMD).
Using specific wavelengths of visible and near-infrared light, Valeda improves cellular function and has been clinically proven to enhance vision.
Benefits:
• Clinically significant improvement in visual acuity (BCVA)
• Reduction in central drusen volume
• Enhanced contrast sensitivity
• Non-invasive, painless, and well-tolerated
• Backed by the 24-month LIGHTSITE III clinical trial
Indications:
• Early to intermediate Dry AMD
• Complementary to standard retinal care
• Delivered in treatment series with short, outpatient sessions
Video: Valeda_Lumithera
